Pneumology - Original Articles Open access

Treatment patterns and survival trends among patients with advanced-stage non-small cell lung cancer in Pakistan: a cancer registry-based flexible parametric analysis

Authors

Published
22 October 2026
Issue
Early Access
Section
Pneumology - Original Articles
DOI
10.4081/monaldi.2026.4380

Abstract

This study aimed to describe trends in survival by treatment modality in advanced-stage (III-IV) non-small cell lung cancer (NSCLC) patients. A retrospective observational study was conducted. Patients diagnosed with primary NSCLC stage III-IV were included from the Cancer Registry of the Aga Khan University Hospital, Karachi, Pakistan. A flexible parametric (Royston-Parmar) model was used to estimate survival trends by treatment modality, sex, and age group. Overall, 663 patients were included; 489 (73.76%) were males. Eighty-one (12.22%) received ‘radiotherapy only’, 217 (32.73%) ‘systemic therapy only’, 136 (20.51%) ‘systemic therapy with radiotherapy’, 34 (5.13%) underwent ‘surgery ± additional treatment’, and 195 (29.41%) did not receive any treatment. Overall, predicted survival increased across all treatment modalities from 2011 to 2019, including the ‘no treatment’ group. In stage III disease, the absolute change in 1- and 2-year survival was most pronounced in the ‘radiotherapy only’ group, at 25.71% and 20.62%, respectively. In stage IV disease, the absolute change in 1-year survival was largest in the ‘no treatment’ group (24.44%) and in 2-year survival in the ‘surgery ± additional treatment’ group (33.46%). For ‘surgery ± additional treatment’ in stage III disease, patients aged >60 years had significantly lower odds of receiving surgery [odds ratio (OR) 0.25, 95% confidence interval (CI) 0.09-0.70, p=0.008]. Among stage IV patients, those diagnosed in 2017-2019 had significantly lower odds of receiving ‘radiotherapy only’ (OR 0.46, 95% CI 0.23-0.92, p=0.027), while squamous cell carcinoma histology was associated with significantly higher odds of receiving ‘radiotherapy only’ (OR 2.23, 95% CI 1.06-4.71, p=0.036). In conclusion, survival improved across all treatment modalities, including among untreated patients. Survival differences across modalities, including with surgical resection and combined therapy, most likely reflect selection of patients with more favorable prognostic profiles. Therefore, these findings should be interpreted as real-world treatment patterns and associated survival trends rather than evidence of comparative treatment efficacy.

Keywords

Ethics Approval

Before commencing the study, a research protocol was submitted for exemption and ethical approval was obtained from the Ethical Review Committee of The Aga Khan University, Karachi, Pakistan (Reference # 2024-10764-31703).

References

  1. Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of lung cancer. Contemp Oncol 2021;25:45-52. DOI: https://doi.org/10.5114/wo.2021.103829
  2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-63. DOI: https://doi.org/10.3322/caac.21834
  3. Zhou J, Xu Y, Liu J, et al. Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol 2024;93:102693. DOI: https://doi.org/10.1016/j.canep.2024.102693
  4. Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer. Lancet 2021;398:535-54. DOI: https://doi.org/10.1016/S0140-6736(21)00312-3
  5. Sheikh HS, Munawar K, Sheikh F, Qamar MFU. Lung cancer in Pakistan. J Thorac Oncol 2022;17:602-7. DOI: https://doi.org/10.1016/j.jtho.2022.01.009
  6. Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. Pakistan. Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/586-pakistan-fact-sheet.pdf.
  7. Yao Y, Fareed R, Zafar A, et al. State-of-the-art combination treatment strategies for advanced stage non-small cell lung cancer. Front Oncol 2022;12:958505. DOI: https://doi.org/10.3389/fonc.2022.958505
  8. AKUH. The Aga Khan University Hospitals. Available from: https://hospitals.aku.edu/Pages/default.aspx.
  9. AKUH. Ca​ncer Registry 2026. Available from: https://www.aku.edu/mcpk/onco/Pages/cancer-registry.aspx.
  10. Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002;21:2175-97. DOI: https://doi.org/10.1002/sim.1203
  11. Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J 2009;9:265-90. DOI: https://doi.org/10.1177/1536867X0900900206
  12. Royston P, Lambert PC. Flexible parametric survival analysis using Stata: beyond the Cox model College Station, TX, USA: Stata Press; 2011.
  13. Rutherford MJ, Crowther M, Lambert PC. The use of restricted cubic splines to approximate complex hazard functions in the analysis of time-to-event data: a simulation study. J Stat Comput Simul 2015;85:777-93. DOI: https://doi.org/10.1080/00949655.2013.845890
  14. Brown S, Banfill K, Aznar MC, et al. The evolving role of radiotherapy in non-small cell lung cancer. Br J Radiol 2019;92:20190524. DOI: https://doi.org/10.1259/bjr.20190524
  15. Simone CB, Bradley J, Chen AB, et al. ASTRO radiation therapy summary of the ASCO guideline on management of stage III non-small cell lung cancer. Pract Radiat Oncol 2023;13:195-202. DOI: https://doi.org/10.1016/j.prro.2023.01.005
  16. Jabbour SK, Daroui P, Moore D, et al. A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. J Thorac Dis 2011;3:4-9.
  17. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017;377:1919-29. DOI: https://doi.org/10.1056/NEJMoa1709937
  18. Lu S, Kato T, Dong X, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med 2024;391:585-97. DOI: https://doi.org/10.1056/NEJMoa2402614
  19. Gouran-Savadkoohi M, Mesci A, Pond GR, et al. Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer. J Thorac Dis 2023;15:423-33. DOI: https://doi.org/10.21037/jtd-22-925
  20. Joo JH, Song SY, Kim SS, et al. Definitive radiotherapy alone over 60 Gy for patients unfit for combined treatment to stage II-III non-small cell lung cancer: retrospective analysis. Radiat Oncol 2015;10:250. DOI: https://doi.org/10.1186/s13014-015-0560-z
  21. Donkor A, Atuwo-Ampoh VD, Yakanu F, et al. Financial toxicity of cancer care in low- and middle-income countries: a systematic review and meta-analysis. Support Care Cancer 2022;30:7159-90. DOI: https://doi.org/10.1007/s00520-022-07044-z
  22. Nwagbara UI, Ginindza TG, Hlongwana KW. Health systems influence on the pathways of care for lung cancer in low- and middle-income countries: a scoping review. Global Health 2020;16:23. DOI: https://doi.org/10.1186/s12992-020-00553-8
  23. Pham J, Conron M, Wright G, et al. Excess mortality and undertreatment in elderly lung cancer patients: treatment nihilism in the modern era? ERJ Open Res 2021;7:00393-2020. DOI: https://doi.org/10.1183/23120541.00393-2020
  24. May L, Shows K, Nana-Sinkam P, et al. Sex differences in lung cancer. Cancers 2023;15:3111. DOI: https://doi.org/10.3390/cancers15123111
  25. Ganti AK, Klein AB, Cotarla I, et al. Update of incidence, prevalence, survival, and initial treatment in patients with non–small cell lung cancer in the US. JAMA Oncol 2021;7:1824-32. DOI: https://doi.org/10.1001/jamaoncol.2021.4932
  26. David EA, Daly ME, Li CS, et al. Increasing rates of no treatment in advanced-stage non-small cell lung cancer patients: a propensity-matched analysis. J Thorac Oncol 2017;12:437-45. DOI: https://doi.org/10.1016/j.jtho.2016.11.2221
  27. Tabchi S, Kassouf E, Florescu M, et al. Factors influencing treatment selection and survival in advanced lung cancer. Curr Oncol 2017;24:e115-22. DOI: https://doi.org/10.3747/co.24.3355
  28. Goulart BH, Reyes CM, Fedorenko CR, et al. Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer. J Oncol Pract 2013;9:42-50. DOI: https://doi.org/10.1200/JOP.2012.000640
  29. Stabellini N, Bruno DS, Dmukauskas M, et al. Sex differences in lung cancer treatment and outcomes at a large hybrid academic-community practice. JTO Clin Res Rep 2022;3:100307. DOI: https://doi.org/10.1016/j.jtocrr.2022.100307
  30. Varela G, Thomas PA. Surgical management of advanced non-small cell lung cancer. J Thorac Dis 2014;6:S217-23.
  31. Ren J, Ren J, Wang K, Tan Q. The consideration of surgery on primary lesion of advanced non-small cell lung cancer. BMC Pulm Med 2023;23:118. DOI: https://doi.org/10.1186/s12890-023-02411-w
  32. Rodriguez-Quintero JH, Jindani R, Zhu R, et al. Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability? JTO Clin Res Rep 2025;6:100766. DOI: https://doi.org/10.1016/j.jtocrr.2024.100766
  33. David EA, Canter RJ, Chen Y, et al. Surgical management of advanced non-small cell lung cancer is decreasing but is associated with improved survival. Ann Thorac Surg 2016;102:1101-9. DOI: https://doi.org/10.1016/j.athoracsur.2016.04.058
  34. Yoo S, Cho WC, Lee GD, et al. Long-term surgical outcomes in oligometastatic non-small cell lung cancer: a single-center study. J Chest Surg 2023;56:25-32. DOI: https://doi.org/10.5090/jcs.22.101
  35. Khan MR, Hasan SB, Sami SA. Non-small cell lung cancer: disease spectrum and management in a tertiary care hospital. J Pak Med Assoc 2000;50:330-3.
  36. Munawar K, Sheikh H. P76.75 clinical outcome and toxicity profiles of patients with EGFR-mutation positive non-small-cell lung cancer. J Thorac Oncol 2021;16:S621-2. DOI: https://doi.org/10.1016/j.jtho.2021.01.1132
  37. Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med 2023;389:137-47. DOI: https://doi.org/10.1056/NEJMoa2304594

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2026 The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.